ArticleOncoTargets and therapy2019
miR-30a-3p Targets MAD2L1 and Regulates Proliferation of Gastric Cancer Cells.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 73 citations in OpenAlex.
- Circulating miRNA-30a is associated with favorable therapeutic outcome in patients with gastric cancer treated with neoadjuvant chemotherapy.Oncology letters · 2026Article
- Integrative bioinformatics and molecular analysis revealed the roles of mTOR/S6K Axis, CASC15, and miR-30a-3p in laryngeal squamous cell carcinoma.Scientific reports · 2026Article
- Transcriptome analysis of goat adipose tissue-derived mesenchymal stem cells cultured in variable oxygen conditions.Frontiers in cell and developmental biology · 2026Article
- Identifying putative causal links between serum circulating microRNAs and thyroid cancer using Mendelian randomization.Discover oncology · 2025Article
- Radiotherapy and precision medicine's role in molecular alterations during chromosomal division: The influence ofBiochemistry and biophysics reports · 2025Article
- Significant prognostic value of cell-cycle proteins in early-stage small cell carcinoma of cervix.Scientific reports · 2025Article
- Investigating the molecular mechanisms, drug prediction, and validation of CCNA2 and MAD2L1 in esophageal squamous cell carcinoma based on bioinformatics.BMC medical genomics · 2025Article
- MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- Identification of MAD2L1 as a novel biomarker for hepatoblastoma through bioinformatics and machine learning approaches.Frontiers in oncology · 2025Article
- Identification of Tumor-SuppressiveNon-coding RNA · 2024Article
- GGT5 as a promising prognostic biomarker and its effects on tumor cell progression in gastric cancer.Translational cancer research · 2024Article
- Upregulated expression ofJournal of gastrointestinal oncology · 2024Article
- Identification and immune landscape analysis of fatty acid metabolism genes related subtypes of gastric cancer.Scientific reports · 2023Article
- MAD2L1 is transcriptionally regulated by TEAD4 and promotes cell proliferation and migration in colorectal cancer.Cancer gene therapy · 2023Article
- Circ_0031242 regulates the functional properties of hepatocellular carcinoma cells through the miR-944/MAD2L1 axis.Histology and histopathology · 2023Article
- MicroRNA signature of small-cell lung cancer after treatment failure: impact on oncogenic targets by miR-30a-3p control.Molecular oncology · 2023Article
- Alarmins and MicroRNAs, a New Axis in the Genesis of Respiratory Diseases: Possible Therapeutic Implications.International journal of molecular sciences · 2023Review
- Evolution of the ErbB gene family and analysis of regulators ofNeural regeneration research · 2022Article
- Identification of key genes associated with cancer stem cell characteristics in Wilms' tumor based on bioinformatics analysis.Annals of translational medicine · 2022Article
- Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was done to investigate the inhibition effects of miR-30a-3p on mitotic arrest deficient 2 like 1 (MAD2L1) expression and the proliferation of gastric cancer cells. PATIENTS AND
methodsCluster analysis and the TCGA database were used to screen the key genes highly expressed in gastric cancer. Based on the LinkedOmics website, the correlation between the miR-30a-3p and the cell cycle-related target gene
resultsBioinformatics analysis showed that MAD2L1 was highly expressed in tumor tissues compared with normal tissues. Compared with normal tissues, the miR-30a-3p was significantly decreased in the gastric cancer tissues. Moreover, MAD2L1 was significantly negatively correlated with the miR-30a-3p expression. Furthermore, over-expression of miR-30a-3p decreased the expression of MAD2L1 at the protein level, which inhibited the proliferation of AGS and BGC-823 gastric cancer cells. In addition, the cell cycles of AGS and BGC-823 cells were arrested at the G0/G1 phase.
conclusionMAD2L1 is a pro-oncogene which is up-regulated in gastric cancer. The miR-30a-3p can down-regulate the MAD2L1 expression, inhibiting the proliferation of gastric cancer cells and affect the cell cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.